Emergence of Carbapenem Non-susceptible Campylobacter coli after Long-term Treatment against Recurrent Bacteremia in a Patient with X-linked Agammaglobulinemia

Internal Medicine
Hideharu HagiyaKazunori Tomono

Abstract

We herein report a case of recurrent Campylobacter coli bacteremia in a 37-year-old Japanese man with X-linked agammaglobulinemia (XLA). The patient experienced seven episodes of C. coli bacteremia over one year, with an erythematous rash intermittently emerged on the lower limbs. Although hospitalization for intravenous treatment was repeatedly recommended, he obstinately declined it. Following long-term oral antibiotic treatment with tebipenem and faropenem for the persistent infection, C. coli showed elevated minimum inhibitory concentrations to meropenem, a key drug for severe campylobacteriosis. Physicians should note that the overuse of antibiotics can lead to the emergence of carbapenem-non-susceptible Campylobacter strains.

References

Jan 1, 1995·Scandinavian Journal of Infectious Diseases·H C SchønheyderW Frederiksen
Jun 1, 1993·Epidemiology and Infection·M B SkirrowJ Benjamin
Mar 1, 1997·Trends in Microbiology·K G Wooldridge, J M Ketley
Nov 14, 2003·The Journal of Antimicrobial Chemotherapy·Antti J HakanenPirkko Kotilainen
Apr 20, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael C SamuelUNKNOWN Emerging Infections Program FoodNet Working Group
Jun 15, 2004·The Pediatric Infectious Disease Journal·Koichi TokudaMasao Yoshinaga
Sep 1, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A MonseliseM Weinberger
Jan 22, 2005·Immunological Reviews·Mary Ellen ConleySheila A Shurtleff
May 24, 2006·Microbes and Infection·John E MooreOla Tolba
Aug 14, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jérôme PacanowskiUNKNOWN CAMPYL Study Group
May 15, 2009·Clinical and Experimental Immunology·I M E DesarJ W M van der Meer
Aug 14, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H NielsenH C Schønheyder
Jun 18, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T van den BrueleR G M Bredius
Feb 26, 2011·International Journal of Food Microbiology·Shang-Shang QinJian-Zhong Shen
Sep 17, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin FeodoroffHilpi Rautelin
May 23, 2013·The Pediatric Infectious Disease Journal·Shalom Ben-ShimolDavid Greenberg
Jul 19, 2013·Case Reports in Pediatrics·Paola AriganelloCaterina Cancrini
Mar 1, 2012·European Journal of Microbiology & Immunology·R LouwenH P Endtz
Sep 2, 2014·Internal Medicine·Takehiko MoriSatoshi Iwata
Oct 10, 2014·Transplant Infectious Disease : an Official Journal of the Transplantation Society·L PereiraM Pestana
Jun 13, 2015·Clinical Microbiology Reviews·Nadeem O KaakoushSi Ming Man
Aug 17, 2016·Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases·Keiji TasakaGo Yamamoto

❮ Previous
Next ❯

Citations

Feb 23, 2020·Journal of Clinical Medicine·Iris NajjarPhilip E Tarr
Dec 30, 2020·BMJ Case Reports·Sindhura PisipatiYousaf Zafar
Jun 1, 2021·Frontiers in Cellular and Infection Microbiology·Daise Aparecida RossiRoberta Torres de Melo
Aug 10, 2021·Pharmacotherapy·Varun SodhiJonathan C Cho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Campylobacteriosis

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Campylobacteriosis (ASM)

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.